GSK plc
GSK
$38.40
$0.441.16%
NYSE
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 1.39% | 3.93% | 1.08% | 10.69% | 10.62% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 1.39% | 3.93% | 1.08% | 10.69% | 10.62% |
| Cost of Revenue | -0.21% | 11.87% | 6.67% | 9.43% | 5.09% |
| Gross Profit | 1.95% | 0.68% | -1.05% | 11.15% | 12.70% |
| SG&A Expenses | 3.39% | 3.65% | 75.03% | 6.67% | 0.08% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -18.40% | 130.93% | 62.32% | 32.81% | 12.40% |
| Total Operating Expenses | 0.99% | 15.58% | 40.27% | 10.38% | 6.26% |
| Operating Income | 2.29% | -39.57% | -75.21% | 11.50% | 22.02% |
| Income Before Tax | 54.52% | 53.15% | -96.33% | -24.17% | -25.80% |
| Income Tax Expenses | 21.80% | 436.43% | -100.40% | -20.46% | 3.67% |
| Earnings from Continuing Operations | 62.81% | 29.78% | -95.64% | -24.69% | -30.79% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -320.00% | -86.87% | -80.60% | -9.11% | 74.08% |
| Net Income | 54.21% | 21.95% | -104.07% | -27.21% | -26.69% |
| EBIT | 2.29% | -39.57% | -75.21% | 11.50% | 22.02% |
| EBITDA | 11.44% | -18.37% | -50.27% | 17.21% | 13.92% |
| EPS Basic | 53.47% | 21.18% | -104.05% | -27.67% | -27.13% |
| Normalized Basic EPS | -5.06% | -48.50% | -85.83% | 12.18% | 39.99% |
| EPS Diluted | 53.68% | 20.94% | -104.10% | -27.65% | -27.32% |
| Normalized Diluted EPS | -5.19% | -48.55% | -85.84% | 12.10% | 39.94% |
| Average Basic Shares Outstanding | 0.47% | 0.62% | 0.62% | 0.64% | 0.62% |
| Average Diluted Shares Outstanding | 0.58% | 0.70% | 0.71% | 0.71% | 0.69% |
| Dividend Per Share | 5.94% | 3.12% | 10.10% | 7.99% | 11.88% |
| Payout Ratio | -0.31% | -0.09% | -28.24% | 0.62% | 0.46% |